# Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/myelodysplastic-syndromes-developing-drug-and-biological-products-for-treatment-draft-guidance-for-industry/4c1a6b62-5c53-485e-9004-1b388e3f1bf3

> FDA guidance document: Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry. Issue date: July 02, 2025. Get complete insights and analysis.

---

## Details

- Title: Myelodysplastic Syndromes: Developing Drug and Biological Products for Treatment: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2025-07-02
- Comment Close Date: 2025-09-01
- Last Changed: 2025-07-02
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2025-D-0649">FDA-2025-D-0649</a>

## Related Documents

- [Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology](https://www.globalkeysolutions.net/guidances/guidance-document/prevention-and-treatment-of-chemotherapy-induced-peripheral-neuropathy-developing-drug-and-biological-products-in-oncology/21c15304-ad79-4fb0-8609-1712f3c9952b)
- [Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/acute-myeloid-leukemia-developing-drugs-and-biological-products-for-treatment-draft-guidance-for-industry/8143a606-18fc-488c-b3ab-4c23bdcd999a)
- [Osteoarthritis: Structural Endpoints for the Development of Drugs](https://www.globalkeysolutions.net/guidances/guidance-document/osteoarthritis-structural-endpoints-for-the-development-of-drugs/8fba9dbf-fb3b-42a9-8837-a2ce4870eba1)